NY-APTORUM-GROUP-LIMITED
30.3.2020 14:02:14 CEST | Business Wire | Press release
Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas, today announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and has also entered into agreement with the University of Hong Kong’s Microbiology Department to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies to initiate clinical trials on suitable candidates.
In particular, Aptorum Group will focus on investigation of at least three small molecule drugs (collectively “SACT-COV19”), that have shown potential interference against two enzyme targets, namely, 3CL-Protease and RNA dependent RNA Polymerase (“RDRP”), with both playing pivotal roles in COVID-19’s replication cycle. Specifically, 3CL-Protease is believed to mediate viral replication and transcription functions through extensive proteolytic processing, while RDRP is an enzyme that is believed to catalyze the replication of viral RNA from its RNA template. These selected candidates will undergo further preclinical assessment on efficacy against COVID-19. Aptorum Group has filed patent applications on the above candidates.
For the ongoing investigation and preclinical work, Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and also Aptorum Group has contracted with the University of Hong Kong to conduct this work. Covar Pharmaceutical’s team (comprised of professionals previously from Patheon and Glaxo Wellcome)1 is highly experienced in drug discovery and development supported by its GMP manufacturing facility. The University of Hong Kong’s Microbiology team was instrumental in the discovery of SARS virus during the 2003 epidemic2 , as well as currently being actively involved, in their own respective research interests, in developing vaccines for SARS-CoV-2 coronavirus3 and COVID-19 related monitoring physical device with other third parties4 .
Aptorum Group will also seek additional collaborators globally for driving its development of SACT-COV19 initiatives forward and welcomes interested parties to contact us to discuss collaboration opportunities.
Aptorum Group, as part of its existing pipeline, is also developing a number of infectious disease indications under its Acticule platform, including, but not limited to, a unique antiviral small molecule candidate (ALS-1) against Influenza virus and also, as its lead program, an anti-virulent, non-bactericidal small molecule candidate (ALS-4) against Staphylococcus aureus infections, amongst other projects, for which Covar Pharmaceuticals is also currently supporting its development in North America.
Mr. Ian Huen, Chief Executive Officer of Aptorum Group said, “COVID-19 disease is highly contagious and has spread across the world causing significant disruptions and casualties in the process. The confirmed cases globally have exceeded 700,000 as of today’s date5 and the World Health Organization has declared COVID-19 as a pandemic. Despite a growing number of both established and early stage pharmaceutical companies rushing to develop vaccine based therapies for COVID-19, we believe there is a need to tackle this disease multi-dimensionally and urgently. In order to accelerate development, our aim is to identify candidates from already approved drugs, that have established safety, toxicity and pharmacokinetic clinical profiles, to be repurposed for treatment of COVID-19. In addition, due to the ongoing mutation and evolution of this coronavirus, we cannot rule out that there may be further strains of this coronavirus emerging in the near future and therefore, the world must be prepared to deal with such challenges swiftly and collectively in order to minimize casualties and economic loss. We believe that Aptorum Group’s Smart-ACT™ platform in conjunction with our existing Acticule infectious disease development capabilities and as supported by Covar Pharmaceuticals, is well-positioned to develop potential solutions and to deliver our share of contribution to the world on this disease as well as others.”
About Smart-ACT™ Platform
The Smart-ACT™ platform is a proprietary systematic process combining both computational approach and wet laboratory validation under which Aptorum Group constantly screens over 2,600 approved small molecule drugs in order to identify candidates that can be repurposed for selected orphan or unmet diseases. The overall strategic aim is to significantly shorten R&D costs and the timeline to effectively deliver patentable repurposed drug candidates into clinical trials and efficiently achieve eventual market commercialization.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group's current drug pipeline include indications in orphan diseases, infectious diseases and metabolic diseases and a number of which are targeted to enter clinical trial phases in 2020. Aptorum Group’s Dioscorea Opposita Bioactive Nutraceutical Tablets, which is a dietary supplement for women’s health during menopause and post-menopause cycles, are currently being commercialized.
For more information about Aptorum Group, please visit www.aptorumgroup.com .
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
1 https://www.covarpharma.com/
2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747526/
3 https://fightcovid19.hku.hk/tag/vaccine/
5 https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005263/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Releases The Xsolla Report: Mobile D2C Edition28.9.2026 15:00:00 CEST | Press release
New Data From More Than 800 Mobile Web Shops Finds Direct-to-Consumer Has Become a Standard Operating Discipline, With Top Performers Capturing More Than Half of a Title's Revenue Regardless of Studio Size Xsolla, a global commerce company, today released The Xsolla Report: Mobile D2C Edition, a new study examining how direct-to-consumer commerce is performing across mobile games. Drawing on data from more than 800 live Xsolla Web Shops alongside public market and regulatory data, the report shows that D2C has moved past the question of whether it works and into a new phase: studios seeing the strongest results are the ones treating their Web Shop as an operating discipline rather than a one-time build. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928312597/en/ Graphic: Xsolla Three themes run through the report. First, the gap between a typical Web Shop and a top-performing one is wide, and closing it has little to do
Incognito Software Systems Launches NEXA, an AI-Enabled Solution for Automated Broadband Operations28.9.2026 15:00:00 CEST | Press release
NEXA unifies network, device, service, and subscriber data to help broadband service providers identify issues earlier, improve customer experience, reduce churn, and automate operations. Incognito Software Systems, a leading global provider of service orchestration, device management, and network intelligence solutions, today introduced NEXA, an AI-driven network intelligence and automation platform that enables broadband service providers to turn operational data into action. NEXA unifies network, device, service, and subscriber data in a single intelligence layer, delivering real-time and predictive insights that help service providers identify issues sooner, better understand the subscriber experience, and take faster, more informed action across their operations. As service providers seek to differentiate beyond connectivity, subscriber experience has become a critical competitive advantage. However, networks have evolved into complex service platforms that span access, edge, cust
Volante Technologies and Circle advance stablecoin payment and settlement capabilities for financial institutions28.9.2026 15:00:00 CEST | Press release
Collaboration enables banks to integrate USDC workflows within existing multi-rail payments infrastructure Volante Technologies, the global leader in Payments as a Service (PaaS), today announced a strategic collaboration with Circle Internet Group, Inc. (NYSE: CRCL) (“Circle”), a leading internet financial platform company and the issuer of USDC1 through its regulated entities, to help financial institutions integrate stablecoin payment and settlement capabilities into their existing payment operations. Through the collaboration, Volante is bringing USDC workflows into its AI-powered Payments Platform, enabling financial institutions to evaluate how stablecoin activity can operate alongside existing payment rails, operational controls, and on- and off-ramp requirements - without requiring a separate digital asset stack. Volante clients, which include four of the top five global corporate banks and seven of the top 10 U.S. banks, will be able to evaluate key workflows, including mintin
Zayed Sustainability Prize Unveils 2027 Finalists Following Record-Breaking Global Entry28.9.2026 14:47:00 CEST | Press release
Record 10,233 submissions from 177 countries, up 32% year-on-yearFinalists are delivering practical, scalable solutions across health, food, energy, water and climate actionPrize has positively impacted more than 411 million lives worldwide From AI that can predict pregnancy complications months in advance and robots that navigate water networks, to new technologies restoring degraded soil and heat-resilient corals rebuilding reefs, the Zayed Sustainability Prize has unveiled its 2027 finalists following the most competitive cycle in its history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928805335/en/ Members of the Zayed Sustainability Prize Jury gathered in Abu Dhabi to determine the 2027 winners and finalists (Photo: AETOSWire) A record 10,233 submissions from 177 countries were received for the 2027 cycle, a 32% increase year-on-year, reflecting the growing global reach of the UAE’s pioneering award for innovativ
ZincFive Expands Nickel-Zinc Technology into In-Rack Backup and AI Dynamic Power Solutions28.9.2026 14:05:00 CEST | Press release
Applying proven high-rate nickel-zinc technology to in-rack backup and AI-driven transient power applications ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced its expansion into in-rack energy storage with the development of Battery Backup Unit (BBU) and AI Dynamic Power Module (DPM) solutions designed to address the evolving energy storage requirements of AI data centers. As AI drives higher rack power densities and increasingly dynamic workloads, data center power architectures are evolving to manage both traditional backup requirements and rapid, repeated changes in power demand. These transient loads can place significant stress on electrical infrastructure, creating a growing need for power solutions closer to the rack that can respond quickly, safely, and reliably. Today’s rack-level technologies often require tradeoffs between energy capacity and dynamic power response. Traditional BBUs are primarily designed t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom